FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240629617> ?p ?o ?g. }

• W4240629617 endingPage "232" @default.
• W4240629617 startingPage "231" @default.
• W4240629617 abstract "Our experience with off-label use of botulinum toxin continues to grow. As our experience using this treatment for neurogenic and non-neurogenic overactive bladder increases, we find that, while certain questions are being answered, more questions are surfacing. The pediatric urological literature has shown that patients injected with botulinum toxin demonstrate a reduction in incontinence episodes, an increase in bladder capacity, and a reduction in dangerous detrusor pressures—results that appear to last 6-9 months. The questions that remain to be answered center on technique, location of injection, risk of incomplete bladder emptying, and need for clean intermittent catheterization, the risk of systemic side effects, and the long-term outcome of repeat injections. In a recent review, the amount of botulinum toxin type A (BTX-A), Botox, injected most commonly was 10-12 U/kg, with a maximum dose of 300 U, usually in the form of 30 injections of 10 U/mL in the bladder, excluding the trigone. Most of these patients were injected under local anesthesia. 1 Gamé X. Mouracade P. Chartier-Kastler E. et al. Botulinum toxin-A (Botox®) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol. 2009; 5: 156-164 Abstract Full Text Full Text PDF PubMed Scopus (86) Google Scholar Another recent study showed a significant improvement in the quality of life of patients injected with Botox and a 43% incidence of clean intermittent self-catheterization (a postvoid residual greater than 100 mL with lower urinary tract symptoms). 2 Khan S. Kessler T.M. Apostolidis A. et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection. J Urol. 2009; 181: 1773-1778 Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar Intravesical Injections of Botulinum Toxin Type A for Management of Neuropathic Bladder: A Comparison of Two MethodsUrologyVol. 76Issue 1PreviewTo evaluate and compare the efficacy of botulinum toxin intravesical injections with and without injections in external urethral sphincter in treating bladder hyper-reflexia in children suffering from myelomeningocele. Full-Text PDF ReplyUrologyVol. 76Issue 1PreviewWe agree that still there is a lot to be understood considering the injections of botulinum toxin type A (BT-A) for treating hyperactive bladder in children with neuropathic bladder. For revealing more aspects of this subject researches are ongoing at ur center for providing information for further perception of this management. Moreover, we have designed a randomized clinical trial, comparing the results of 3 groups of children receiving injections of BT-A into detrusor only, external urethral sphincter only, and both. Full-Text PDF" @default.
• W4240629617 created "2022-05-12" @default.
• W4240629617 creator A5076856473 @default.
• W4240629617 date "2010-07-01" @default.
• W4240629617 modified "2023-09-27" @default.
• W4240629617 title "Editorial Comment" @default.
• W4240629617 doi "https://doi.org/10.1016/j.urology.2009.10.059" @default.
• W4240629617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20599119" @default.
• W4240629617 hasPublicationYear "2010" @default.
• W4240629617 type Work @default.
• W4240629617 citedByCount "0" @default.
• W4240629617 crossrefType "journal-article" @default.
• W4240629617 hasAuthorship W4240629617A5076856473 @default.
• W4240629617 hasConcept C126894567 @default.
• W4240629617 hasConcept C141071460 @default.
• W4240629617 hasConcept C142724271 @default.
• W4240629617 hasConcept C204787440 @default.
• W4240629617 hasConcept C2777478456 @default.
• W4240629617 hasConcept C2778531004 @default.
• W4240629617 hasConcept C2778941218 @default.
• W4240629617 hasConcept C2779762690 @default.
• W4240629617 hasConcept C2781036200 @default.
• W4240629617 hasConcept C2910833680 @default.
• W4240629617 hasConcept C42219234 @default.
• W4240629617 hasConcept C55034048 @default.
• W4240629617 hasConcept C71924100 @default.
• W4240629617 hasConceptScore W4240629617C126894567 @default.
• W4240629617 hasConceptScore W4240629617C141071460 @default.
• W4240629617 hasConceptScore W4240629617C142724271 @default.
• W4240629617 hasConceptScore W4240629617C204787440 @default.
• W4240629617 hasConceptScore W4240629617C2777478456 @default.
• W4240629617 hasConceptScore W4240629617C2778531004 @default.
• W4240629617 hasConceptScore W4240629617C2778941218 @default.
• W4240629617 hasConceptScore W4240629617C2779762690 @default.
• W4240629617 hasConceptScore W4240629617C2781036200 @default.
• W4240629617 hasConceptScore W4240629617C2910833680 @default.
• W4240629617 hasConceptScore W4240629617C42219234 @default.
• W4240629617 hasConceptScore W4240629617C55034048 @default.
• W4240629617 hasConceptScore W4240629617C71924100 @default.
• W4240629617 hasIssue "1" @default.
• W4240629617 hasLocation W42406296171 @default.
• W4240629617 hasLocation W42406296172 @default.
• W4240629617 hasOpenAccess W4240629617 @default.
• W4240629617 hasPrimaryLocation W42406296171 @default.
• W4240629617 hasRelatedWork W1969146667 @default.
• W4240629617 hasRelatedWork W2597402884 @default.
• W4240629617 hasRelatedWork W2795508039 @default.
• W4240629617 hasRelatedWork W4237573662 @default.
• W4240629617 hasRelatedWork W4240629617 @default.
• W4240629617 hasRelatedWork W4251812555 @default.
• W4240629617 hasRelatedWork W4256631357 @default.
• W4240629617 hasRelatedWork W4289777435 @default.
• W4240629617 hasRelatedWork W4323363238 @default.
• W4240629617 hasRelatedWork W69721835 @default.
• W4240629617 hasVolume "76" @default.
• W4240629617 isParatext "false" @default.
• W4240629617 isRetracted "false" @default.
• W4240629617 workType "editorial" @default.